DK3350327T3 - Konstrueret crispr-klasse-2-nucleinsyre-targeting-nucleinsyre - Google Patents

Konstrueret crispr-klasse-2-nucleinsyre-targeting-nucleinsyre Download PDF

Info

Publication number
DK3350327T3
DK3350327T3 DK16794469.3T DK16794469T DK3350327T3 DK 3350327 T3 DK3350327 T3 DK 3350327T3 DK 16794469 T DK16794469 T DK 16794469T DK 3350327 T3 DK3350327 T3 DK 3350327T3
Authority
DK
Denmark
Prior art keywords
natna
cas9
cpfl
protein
nucleic acid
Prior art date
Application number
DK16794469.3T
Other languages
English (en)
Inventor
Paul Daniel Donohoue
Andrew Paul May
Original Assignee
Caribou Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Caribou Biosciences Inc filed Critical Caribou Biosciences Inc
Application granted granted Critical
Publication of DK3350327T3 publication Critical patent/DK3350327T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (16)

1. Konstrueret CRISPR-klasse-2-krydstype-nucleinsyre-targeting-nucleinsyre ("CRISPR Class 2 cross-type-NATNA") der omfatter: en Cpfl-associeret nucleinsyre-targeting-nucleinsyre der har en 5'-ende og en 3'-ende, der omfatter et spacer-element ("Cpfl-NATNA"); en første Cas9-associeret nucleinsyre-targeting-nucleinsyre med en 5'-ende og en 3'-ende, der omfatter et spacer-element ("første Cas9-NATNA"); og en anden Cas9-associeret nucleinsyre-targeting-nucleinsyre med en 5'-ende og en 3'-ende, der omfatter et spacer-element ("anden Cas9-NATNA"); hvor den første Cas9-NATNA eller den anden Cas9-NATNA er forbundet med Cpfl-NATNA’en.
2. Konstrueret CRISPR-klasse-2-krydstype-NATNA ifølge krav 1, hvor den første Cas9-NATNA eller den anden Cas9-NATNA: ikke er kovalent forbundet med Cpfl-NATNA’en gennem hydrogenbase-par-binding ved 5'-enden eller 3'-enden af den første Cas9-NATNA eller gennem hydrogenbasepar-binding ved 5'-enden eller 3'-enden af den anden Cas9-NATNA, eller er kovalent forbundet med Cpfl-NATNA’en; og hvor Cpfl-NATNA’en er kovalent forbundet med 5'-enden eller 3'-enden af den første Cas9-NATNA eller til 5'-enden eller 3'-enden af den anden Cas9-NATNA.
3. Konstrueret CRISPR-klasse-2-krydstype-NATNA ifølge krav 1 eller 2, hvor Cpfl-NATNA’en er i stand til at danne et første kompleks med et Cpfl-protein ("Cas9-Cpfl-NATNA/Cpfl-proteinkompleks"); og hvor den første Cas9-NATNA og den anden Cas9-NATNA er i stand til at danne et andet kompleks med et Cas9-protein ("Cas9-Cpfl-NATNA/Cas9-proteinkompleks").
4. Konstrueret CRISPR-klasse-2-krydstype-NATNA ifølge krav 3, hvor det første kompleks er i stand til at binde en første dobbeltstrenget nuc-leinsyre-targetsekvens komplementært til Cpfl-spacer-elementet, hvis Cpfl- NATNA’en danner det første kompleks med Cpfl-proteinet ("Cpfl-NATNA/Cpfl-proteinkomplekset"), og hvor det andet kompleks er i stand til at binde en anden dobbeltstrenget nucleinsyre-targetsekvens komplementært til det første Cas9-NATNA-spacer-element, hvis den første Cas9-NATNA og den anden Cas9-NATNA danner det andet kompleks med Cas9-proteinet ("Cas9-NATNA/Cas9-proteinkomplekset") sekvens komplementær, eller hvor, hvis det første kompleks er dannet og det andet kompleks er dannet hvilket resulterer i et Cas9-Cpfl-NATNA/Cas9 & Cpfl-proteinkompleks, Cas9-Cpfl-NATNA/Cas9 & Cpfl-proteinkomplekset er i stand til at binde en første dobbeltstrenget nucleinsyre-targetsekvens komplementært til Cpfl-spacer-elementet og en anden dobbeltstrenget nucleinsyre-targetsekvens komplementært til det første Cas9-NATNA-spacer-element.
5. Konstrueret CRISPR-klasse-2-krydstype-NATNA ifølge et hvilket som helst af de foregående krav, hvor Cpfl-NATNA’en yderligere omfatter en linker-element-nucleotidsekvens, der er kovalent forbundet med 5'-enden eller 3'-enden af Cpfl-NATNA’en og/eller hvor den første Cas9-NATNA yderligere omfatter en linkerelement-nucleotidsekvens, der er kovalent forbundet med 5'-enden eller 3'-enden af den første Cas9-NATNA eller den anden Cas9-NATNA yderligere omfatter en linker-element-nucleotidsekvens, der er kovalent forbundet med 5'- ende eller 3'-enden af den anden Cas9-NATNA.
6. Konstrueret CRISPR-klasse-2-krydstype-NATNA ifølge krav 1, hvor 3'-enden af den første Cas9-NATNA er kovalent forbundet via et loopelement med 5'-enden af den anden Cas9-NATNA, hvilket resulterer i en single-Cas9-NATNA -associeret nucleinsyre-targeting-nucleinsyre ("single-Cas9-NATNA"), der har en 5'-ende og en 3'-ende; og hvor single-Cas9-NATNA’en omfatter den første Cas9-NATNA og den anden Cas9-NATNA.
7. Konstrueret CRISPR-klasse-2-krydstype-NATNA ifølge krav 6, hvor single-Cas9-NATNA’en ikke er kovalent forbundet med Cpfl-NATNA’en gennem hydrogenbasepar-binding ved 5'-enden eller 3'-enden af single-Cas9-NATNA’en, eller er kovalent forbundet med Cpfl-NATNA’en; og hvor Cpfl-NATNA’en er kovalent forbundet med 5'-enden eller 3'-enden af single-Cas9-NATNA’en.
8. Konstrueret CRISPR-klasse-2-krydstype-NATNA ifølge et hvilket som helst af kravene 6 eller 7, hvor single-Cas9-NATNA'en omfatter en linker-element-nucleotidsekvens, der er kovalent forbundet med 5'-enden eller 3'-enden af single-Cas9-NATNA’en og/eller hvor Cpfl-NATNA’en omfatter en linker-element-nucleotidsekvens, der er kovalent forbundet med 5'-enden eller 3'-enden af Cpfl-NATNA’en.
9. Konstrueret CRISPR-klasse-2-krydstype-NATNA ifølge et hvilket som helst af de foregående krav, hvor mindst en af: Cpfl-NATNA, den første Cas9-NATNA eller den anden Cas9-NATNA omfatter RNA og/eller DNA.
10. Nukleinsyre/proteinsammensætning der omfatter: det konstruerede CRISPR-klasse-2-krydstype-NATNA ifølge et hvilket som helst af de foregående krav, et Cas9-protein og et Cpfl-protein, hvor CRISPR-klasse-2-krydstype-NATNA’en eventuelt er i et kompleks med Cas9-proteinet og Cpfl-proteinet.
11. Nukleinsyre/proteinsammensætningen ifølge krav 10, hvor Cpfl-proteinet, Cas9-proteinet eller både Cpfl- og Cas9-proteinerne er enzymatisk inaktive, eller hvor Cpfl-proteinet er enzymatisk inaktivt (dCpfl-protein) eller Cas9-proteinet er enzymatisk inaktivt (dCas9-protein); og hvor nucleinsy-re/proteinsammensætningen yderligere omfatter et donorpolynucleotid, der ikke er kovalent forbundet med dCpfl-proteinet eller dCas9-proteinet.
12. Ekspressionsvektor der omfatter: en eller flere nucleinsyresekvenser, som koder for det konstruerede CRISPR-klasse-2-krydstype-NATNA ifølge et hvilket som helst af kravene 1 til 9.
13. Rekombinant celle der omfatter: en eller flere nucleinsyresekvenser, som koder for det konstruerede CRISPR-klasse-2-krydstype-NATNA ifølge et hvilket som helst af kravene 1 til 9.
14. Kit der omfatter: det konstruerede CRISPR-klasse-2-krydstype-NATNA ifølge et hvilket som helst af kravene 1 til 9; og en buffer; hvor kittet fortrinsvis yderligere omfatter et Cas9-protein, et Cpfl-protein eller både et Cas9-protein og et Cpfl-protein.
15. Fremgangsmåde til binding af DNA der omfatter: at kontakte en første DNA-targetsekvens i DNA'en og en anden DNA-targetsekvens i DNA'en med nucleinsyre/proteinsammensætningen ifølge et hvilket som helst af kravene 10 eller 11, hvorved bindingen af nucleinsyre/proteinsammensætningen til den første DNA-targetsekvens i DNA'en og den anden DNA-targetsekvens i DNA'en gøres mulig, hvor Cpfl-NATNA-spacer-elementet er komplementært til den første DNA-targetsekvens, og Cas9-NATNA-spaceren er komplementær til den anden DNA-targetsekvens, hvilken fremgangsmåde ikke omfatter en fremgangsmåde til terapeutisk behandling af det menneskelige eller animalske legeme.
16. Fremgangsmåde til skæring af DNA der omfatter: at kontakte en første DNA-targetsekvens i DNA'en og en anden DNA-targetsekvens i DNA'en med nucleinsyre/proteinsammensætningen ifølge krav 10, hvorved der letter bindingen af nucleinsy-re/proteinsammensætningen til den første DNA-targetsekvens og den anden DNA-targetsekvens, hvilket resulterer i skæring af den første DNA-targetsekvens og den anden DNA-targetsekvens; hvor Cpfl-NATNA-spacer-elementet er komplementært til den første DNA-targetsekvens, og Cas9-NATNA-spaceren er komplementær til den anden DNA-targetsekvens; og hvor Cas9-proteinet fra den bundne nucleinsyre/proteinsammensætning er i stand til at skære den anden DNA-targetsekvens, og Cpfl-proteinet fra den bundne nucleinsyre/proteinsammensætning er i stand til at skære den første DNA-targetsekvens, hvor fremgangsmåden ikke omfatter en fremgangsmåde til modifikation af en kønslinjegenetisk identitet af et menneske, og hvor fremgangsmåden ikke omfatter en fremgangsmåde til terapeutisk behandling af det menneskelige eller animalske legeme.
DK16794469.3T 2015-10-23 2016-10-21 Konstrueret crispr-klasse-2-nucleinsyre-targeting-nucleinsyre DK3350327T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562245918P 2015-10-23 2015-10-23
PCT/US2016/058294 WO2017070598A1 (en) 2015-10-23 2016-10-21 Engineered crispr class 2 cross-type nucleic-acid targeting nucleic acids

Publications (1)

Publication Number Publication Date
DK3350327T3 true DK3350327T3 (da) 2019-01-21

Family

ID=57281288

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16794469.3T DK3350327T3 (da) 2015-10-23 2016-10-21 Konstrueret crispr-klasse-2-nucleinsyre-targeting-nucleinsyre

Country Status (5)

Country Link
US (11) US9677090B2 (da)
EP (1) EP3350327B1 (da)
DK (1) DK3350327T3 (da)
ES (1) ES2699848T3 (da)
WO (1) WO2017070598A1 (da)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
EP3690044B1 (en) 2014-02-11 2024-01-10 The Regents of the University of Colorado, a body corporate Crispr enabled multiplexed genome engineering
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
IL310721B2 (en) 2015-10-23 2025-11-01 Harvard College Nucleobase editors and uses thereof
WO2017096041A1 (en) * 2015-12-02 2017-06-08 The Regents Of The University Of California Compositions and methods for modifying a target nucleic acid
BR112018011503A2 (pt) 2015-12-07 2018-12-04 Zymergen Inc promotores da corynebacterium glutamicum
US11208649B2 (en) 2015-12-07 2021-12-28 Zymergen Inc. HTP genomic engineering platform
US9988624B2 (en) 2015-12-07 2018-06-05 Zymergen Inc. Microbial strain improvement by a HTP genomic engineering platform
EP3464594A1 (en) * 2016-06-01 2019-04-10 Kws Saat Se Hybrid nucleic acid sequences for genome engineering
CA3209273A1 (en) * 2016-06-02 2017-12-07 Sigma-Aldrich Co. Llc Using programmable dna binding proteins to enhance targeted genome modification
AU2017280353B2 (en) 2016-06-24 2021-11-11 Inscripta, Inc. Methods for generating barcoded combinatorial libraries
EP3478845A4 (en) 2016-06-30 2019-07-31 Zymergen, Inc. METHOD OF GENERATING A GLUCOSE PERMEASE LIBRARY AND USES THEREOF
US10544390B2 (en) 2016-06-30 2020-01-28 Zymergen Inc. Methods for generating a bacterial hemoglobin library and uses thereof
CN110214183A (zh) 2016-08-03 2019-09-06 哈佛大学的校长及成员们 腺苷核碱基编辑器及其用途
WO2018031683A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
KR102622411B1 (ko) 2016-10-14 2024-01-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
WO2018094356A2 (en) * 2016-11-18 2018-05-24 Genedit Inc. Compositions and methods for target nucleic acid modification
EP3555297A1 (en) 2016-12-19 2019-10-23 Editas Medicine, Inc. Assessing nuclease cleavage
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
US12390514B2 (en) 2017-03-09 2025-08-19 President And Fellows Of Harvard College Cancer vaccine
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
KR20240116572A (ko) 2017-03-23 2024-07-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
US11499151B2 (en) 2017-04-28 2022-11-15 Editas Medicine, Inc. Methods and systems for analyzing guide RNA molecules
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
WO2018226880A1 (en) 2017-06-06 2018-12-13 Zymergen Inc. A htp genomic engineering platform for improving escherichia coli
WO2018226900A2 (en) 2017-06-06 2018-12-13 Zymergen Inc. A htp genomic engineering platform for improving fungal strains
US10011849B1 (en) 2017-06-23 2018-07-03 Inscripta, Inc. Nucleic acid-guided nucleases
US9982279B1 (en) 2017-06-23 2018-05-29 Inscripta, Inc. Nucleic acid-guided nucleases
US11866726B2 (en) 2017-07-14 2024-01-09 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
IT201700105372A1 (it) * 2017-09-20 2019-03-20 Fondazione St Italiano Tecnologia Molecola di acido nucleico funzionale e relativo uso
BR112020006601A2 (pt) * 2017-10-02 2020-12-08 Genedit Inc. Rna guia de cpf1 modificado
WO2019071142A1 (en) * 2017-10-06 2019-04-11 The Board Of Trustees Of The University Of Illinois DETECTION OF BIOMARKERS IN FLUID SAMPLES
KR20250107288A (ko) 2017-10-16 2025-07-11 더 브로드 인스티튜트, 인코퍼레이티드 아데노신 염기 편집제의 용도
WO2019094897A1 (en) * 2017-11-13 2019-05-16 The Penn State Research Foundation Sensitive and accurate genome-wide profiling of rna structure in vivo
US20210002609A1 (en) 2017-12-05 2021-01-07 Caribou Biosciences, Inc. Modified lymphocytes
WO2019118879A1 (en) * 2017-12-14 2019-06-20 Donald Danforth Plant Science Center Homologous recombination via transcriptional activation
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
BR112020012064A2 (pt) 2017-12-22 2020-12-01 KWS SAAT SE & Co. KGaA regulação transcricional direcionada usando fatores de transcrição sintéticos
AU2018390965A1 (en) * 2017-12-22 2020-07-02 KWS SAAT SE & Co. KGaA Cpf1 based transcription regulation systems in plants
US11268092B2 (en) 2018-01-12 2022-03-08 GenEdit, Inc. Structure-engineered guide RNA
WO2019152941A1 (en) 2018-02-05 2019-08-08 Caribou Biosciences, Inc. Engineered gut microbes for reduction of reactivation of detoxified drugs
WO2019173248A1 (en) 2018-03-07 2019-09-12 Caribou Biosciences, Inc. Engineered nucleic acid-targeting nucleic acids
CN111788307A (zh) * 2018-03-12 2020-10-16 南京北恒生物科技有限公司 工程化的嵌合向导rna及其用途
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
EP3823633A4 (en) 2018-06-29 2023-05-03 Editas Medicine, Inc. SYNTHETIC LEAD MOLECULES, COMPOSITIONS AND METHODS RELATED THERETO
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
SG11202103917VA (en) 2018-10-16 2021-05-28 Blueallele Llc Methods for targeted insertion of dna in genes
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
SG11202104409YA (en) 2018-10-31 2021-05-28 Zymergen Inc Multiplexed deterministic assembly of dna libraries
EP3911334A4 (en) 2019-01-17 2023-07-26 The Regents of the University of Colorado, a body corporate SMALL MOLECULE REGULATION OF CRISPR-CAS9 USING RNA APTAMERS
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
WO2020176389A1 (en) 2019-02-25 2020-09-03 Caribou Biosciences, Inc. Plasmids for gene editing
CA3132374A1 (en) 2019-03-06 2020-09-10 The Board Of Trustees Of The Leland Stanford Junior University Mesophilic argonaute systems and uses thereof
US11053515B2 (en) 2019-03-08 2021-07-06 Zymergen Inc. Pooled genome editing in microbes
CN113728106A (zh) 2019-03-08 2021-11-30 齐默尔根公司 微生物中的迭代基因组编辑
WO2020191233A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
IL297761A (en) 2020-05-08 2022-12-01 Broad Inst Inc Methods and compositions for simultaneously editing two helices of a designated double-helix nucleotide sequence
US10894812B1 (en) 2020-09-30 2021-01-19 Alpine Roads, Inc. Recombinant milk proteins
US10947552B1 (en) 2020-09-30 2021-03-16 Alpine Roads, Inc. Recombinant fusion proteins for producing milk proteins in plants
AU2021353004A1 (en) 2020-09-30 2023-04-13 Nobell Foods, Inc. Recombinant milk proteins and food compositions comprising the same
EP4347818A2 (en) 2021-06-01 2024-04-10 Arbor Biotechnologies, Inc. Gene editing systems comprising a crispr nuclease and uses thereof
KR20250151430A (ko) 2023-02-15 2025-10-21 아버 바이오테크놀로지스, 인크. 스타스민 2(stmn2) 전사체에서 비정상적인 스플라이싱을 억제하는 유전자 편집 방법
WO2025171210A1 (en) 2024-02-09 2025-08-14 Arbor Biotechnologies, Inc. Compositions and methods for gene editing via homology-mediated end joining
US12480141B2 (en) 2024-04-04 2025-11-25 Alia Therapeutics Srl Type V Cas proteins and applications thereof
WO2026015829A2 (en) 2024-07-12 2026-01-15 Arbor Biotechnologies, Inc. Small reverse transcriptases and gene editing systems comprising such
WO2026015832A2 (en) 2024-07-12 2026-01-15 Arbor Biotechnologies, Inc. Reverse transcriptases and gene editing systems comprising such

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10087431B2 (en) 2010-03-10 2018-10-02 The Regents Of The University Of California Methods of generating nucleic acid fragments
MX2012013037A (es) 2010-05-10 2013-07-29 Univ California Composiciones de endorribonucleasa y metodos de uso de las mismas.
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
WO2013130824A1 (en) 2012-02-29 2013-09-06 Sangamo Biosciences, Inc. Methods and compositions for treating huntington's disease
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
AU2013266968B2 (en) 2012-05-25 2017-06-29 Emmanuelle CHARPENTIER Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
WO2013188638A2 (en) 2012-06-15 2013-12-19 The Regents Of The University Of California Endoribonucleases and methods of use thereof
WO2014022702A2 (en) 2012-08-03 2014-02-06 The Regents Of The University Of California Methods and compositions for controlling gene expression by rna processing
AU2013335451C1 (en) 2012-10-23 2024-07-04 Toolgen Incorporated Composition for cleaving a target DNA comprising a guide RNA specific for the target DNA and Cas protein-encoding nucleic acid or Cas protein, and use thereof
EP2840140B2 (en) 2012-12-12 2023-02-22 The Broad Institute, Inc. Crispr-Cas based method for mutation of prokaryotic cells
IL239344B2 (en) 2012-12-12 2024-06-01 Broad Inst Inc Systems engineering, methods and optimal guiding components for sequence manipulation
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
US20140310830A1 (en) 2012-12-12 2014-10-16 Feng Zhang CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
CN113355357B (zh) 2012-12-12 2024-12-03 布罗德研究所有限公司 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
WO2014093655A2 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
RU2662932C2 (ru) 2013-03-14 2018-07-31 Карибо Биосайенсиз, Инк. Композиции и способы с участием нуклеиновых кислот, нацеленных на нуклеиновые кислоты
CN112301024A (zh) 2013-03-15 2021-02-02 通用医疗公司 使用RNA引导的FokI核酸酶(RFN)提高RNA引导的基因组编辑的特异性
CN120574876A (zh) 2013-08-22 2025-09-02 纳幕尔杜邦公司 使用向导rna/cas内切核酸酶系统的植物基因组修饰及其使用方法
CA2930877A1 (en) 2013-11-18 2015-05-21 Crispr Therapeutics Ag Crispr-cas system materials and methods
US20150376586A1 (en) 2014-06-25 2015-12-31 Caribou Biosciences, Inc. RNA Modification to Engineer Cas9 Activity
US9650617B2 (en) 2015-01-28 2017-05-16 Pioneer Hi-Bred International. Inc. CRISPR hybrid DNA/RNA polynucleotides and methods of use
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
US9580727B1 (en) 2015-08-07 2017-02-28 Caribou Biosciences, Inc. Compositions and methods of engineered CRISPR-Cas9 systems using split-nexus Cas9-associated polynucleotides

Also Published As

Publication number Publication date
US20180346894A1 (en) 2018-12-06
US9677090B2 (en) 2017-06-13
US20200318088A1 (en) 2020-10-08
US20180201913A1 (en) 2018-07-19
US10023853B1 (en) 2018-07-17
EP3350327A1 (en) 2018-07-25
US9745562B2 (en) 2017-08-29
US10138472B2 (en) 2018-11-27
US20180312827A1 (en) 2018-11-01
US10501728B2 (en) 2019-12-10
US20200071684A1 (en) 2020-03-05
US10711258B2 (en) 2020-07-14
US20180119120A1 (en) 2018-05-03
US20170114369A1 (en) 2017-04-27
US20170204388A1 (en) 2017-07-20
US11225649B2 (en) 2022-01-18
ES2699848T3 (es) 2019-02-13
WO2017070598A1 (en) 2017-04-27
US10125354B1 (en) 2018-11-13
US9816081B1 (en) 2017-11-14
US20190040373A1 (en) 2019-02-07
US20190112587A1 (en) 2019-04-18
US10196619B1 (en) 2019-02-05
US9957490B1 (en) 2018-05-01
EP3350327B1 (en) 2018-09-26

Similar Documents

Publication Publication Date Title
US11225649B2 (en) Engineered nucleic-acid targeting nucleic acids
US11001843B2 (en) Engineered nucleic acid-targeting nucleic acids
EP3371310B1 (en) Engineered nucleic-acid targeting nucleic acids
US20170058272A1 (en) Directed nucleic acid repair
WO2019173248A1 (en) Engineered nucleic acid-targeting nucleic acids
HK40005733B (en) Engineered nuceic acid-targeting nucleic acids
HK40010042B (en) Engineered nucleic-acid targeting nucleic acids
HK40010042A (en) Engineered nucleic-acid targeting nucleic acids